The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Sp823
MAXIMIZING OUTCOMES DURING SURVEILLANCE ENDOSCOPY: REDUCING RATES OF PEEC IN CLINICAL PRACTICE
Date
May 8, 2023
Explore related products in the following collection:
Barrett's esophagus is the only precancerous condition for esophageal adenocarcinoma; a cancer that is associated with rising incidence and high morbidity and mortality rates. This session will highlight the recent advances, controversies and knowledge gaps in the field of screening, surveillance and endoscopic eradication therapies. This session will also include a presentation on the current status and future directions for quality metrics in Barrett's esophagus.
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
BACKGROUND AND AIMS: Chemoresistance is a major cause of colorectal cancer (CRC) recurrence and death. The critical role of gut microbiome in the efficacy of CRC chemotherapy remains unclear…
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…